Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study findsReuters • 07/30/25
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionGlobeNewsWire • 07/25/25
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025GlobeNewsWire • 07/21/25
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th AnniversaryGlobeNewsWire • 07/21/25
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressGlobeNewsWire • 07/10/25
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressBusiness Wire • 07/10/25
Biogen Begins Phase III Felzartamab Study for Third Kidney DiseaseZacks Investment Research • 07/01/25
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyGlobeNewsWire • 06/30/25
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAGlobeNewsWire • 06/27/25
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsGlobeNewsWire • 06/25/25
20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacksMarket Watch • 06/18/25
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaGlobeNewsWire • 06/18/25
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease ActivityGlobeNewsWire • 06/12/25
Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/10/25
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsGlobeNewsWire • 06/03/25
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based TherapiesGlobeNewsWire • 05/27/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior PrincipalGlobeNewsWire • 05/12/25